Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224893 · ClinicalTrials.gov registry record · Phase 4
Once-Daily vs Twice-Daily Insulin Glargine in Pregestational Diabetes Management
A Phase 4 study, sponsored by Eastern Virginia Medical School.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
NCT07224893 is a Phase 4 study that is actively recruiting participants, run by Eastern Virginia Medical School. The registered enrollment target is 200 participants.
The verdict
NCT07224893, a Phase 4 study, is actively recruiting participants, sponsored by Eastern Virginia Medical School.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if taking insulin glargine twice a day instead of once a day will better manage pregestational diabetes in pregnant patients. Participants in this study will be randomly assigned to one of two groups: a group that takes insulin glargine once a day, and a group that takes it twice. Continuous glucose monitoring will be used to track blood sugar levels. The main question the study aims to answer is: Will using insulin glargine twice a day instead of once lead to a better glucose time in range?
Interventions
- DRUG Use of insulin glargine once daily
- DRUG Use of insulin glargine twice daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-05-18 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224893
The ClinicalTrials.gov registry entry for NCT07224893 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Virginia Medical School, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Use of insulin glargine once daily is the first listed.
NCT07224893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07224893 about?
NCT07224893 is a clinical study titled "Once-Daily vs Twice-Daily Insulin Glargine in Pregestational Diabetes Management". The purpose of this study is to determine if taking insulin glargine twice a day instead of once a day will better manage pregestational diabetes in pregnant patients. Participants in this study will be randomly assigned to one of two groups: a group that takes insulin glargine once a day, and a gro...
What is the current status of trial NCT07224893?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2026-05-18. Estimated completion is 2027-12-01.
What interventions are being tested in trial NCT07224893?
The interventions under investigation include: Use of insulin glargine once daily (DRUG), Use of insulin glargine twice daily (DRUG).
Who is sponsoring clinical trial NCT07224893?
This trial is sponsored by Eastern Virginia Medical School, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.